Free Trial
NASDAQ:OTLK

Oncobiologics (OTLK) Stock Price, News & Analysis

Oncobiologics logo
$1.89 +0.03 (+1.61%)
Closing price 04:00 PM Eastern
Extended Trading
$1.90 +0.01 (+0.26%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Oncobiologics Stock (NASDAQ:OTLK)

Key Stats

Today's Range
$1.84
$1.93
50-Day Range
$1.41
$2.03
52-Week Range
$0.87
$9.25
Volume
616,885 shs
Average Volume
832,795 shs
Market Capitalization
$63.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60
Consensus Rating
Moderate Buy

Company Overview

Oncobiologics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

OTLK MarketRank™: 

Oncobiologics scored higher than 33% of companies evaluated by MarketBeat, and ranked 729th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oncobiologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Oncobiologics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Oncobiologics' stock forecast and price target.
  • Earnings Growth

    Earnings for Oncobiologics are expected to grow in the coming year, from ($2.27) to ($0.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncobiologics is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncobiologics is -2.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Oncobiologics' valuation and earnings.
  • Percentage of Shares Shorted

    12.91% of the float of Oncobiologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncobiologics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Oncobiologics has recently decreased by 14.91%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Oncobiologics does not currently pay a dividend.

  • Dividend Growth

    Oncobiologics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.91% of the float of Oncobiologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncobiologics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in Oncobiologics has recently decreased by 14.91%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Oncobiologics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 8 people have searched for OTLK on MarketBeat in the last 30 days. This is a decrease of -47% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Oncobiologics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncobiologics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of Oncobiologics is held by insiders.

  • Percentage Held by Institutions

    Only 11.20% of the stock of Oncobiologics is held by institutions.

  • Read more about Oncobiologics' insider trading history.
Receive OTLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter.

OTLK Stock News Headlines

OTLK Outlook Therapeutics, Inc. - Seeking Alpha
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

OTLK Stock Analysis - Frequently Asked Questions

Oncobiologics' stock was trading at $1.89 on January 1st, 2025. Since then, OTLK shares have increased by 0.0% and is now trading at $1.89.

Oncobiologics, Inc. (NASDAQ:OTLK) issued its earnings results on Thursday, May, 15th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.15.

Shares of Oncobiologics reverse split on the morning of Thursday, March 14th 2024.The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
5/15/2025
Today
7/08/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OTLK
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.60
High Stock Price Target
$21.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+405.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$75.37 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($3.09) per share
Price / Book
-0.61

Miscellaneous

Free Float
31,957,000
Market Cap
$63.78 million
Optionable
Optionable
Beta
0.25
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:OTLK) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners